Prediction of the amitriptyline response: psychopathology versus neuroendocrinology

Int Clin Psychopharmacol. 1986 Oct;1(4):284-95. doi: 10.1097/00004850-198610000-00002.

Abstract

In this prediction study 50 patients with DSM-III major depressive episode were assessed before treatment with respect to symptomatology (Newcastle and Hamilton features), diagnostic sub-types (according to the Newcastle scale and the DSM-III) and neuroendocrinology (DST and TRH-test). Subjects were given 150 mg of amitriptyline daily and the treatment response was determined on day 11 and 21. The duration of hospitalization served as a further criterion of outcome. The data suggest that neither diagnostic sub-typing nor neuroendocrinological variables were significantly related to outcome. Prediction, however, became possible using the following clinical parameters: DSM-III depressive psychotic features, DSM-III personality disorder and sudden onset of illness were significantly associated with poor treatment response and explained 34% of the outcome variance.

Publication types

  • Clinical Trial
  • Comparative Study

MeSH terms

  • Adult
  • Amitriptyline / therapeutic use*
  • Clinical Trials as Topic
  • Depressive Disorder / diagnosis
  • Depressive Disorder / drug therapy*
  • Dexamethasone
  • Female
  • Humans
  • Male
  • Middle Aged
  • Thyroid Function Tests
  • Thyroid Gland / physiopathology
  • Thyrotropin / blood
  • Thyrotropin-Releasing Hormone / blood

Substances

  • Amitriptyline
  • Thyrotropin-Releasing Hormone
  • Dexamethasone
  • Thyrotropin